Profile cover photo
Profile photo
EFPIA
38 followers -
healthcare; pharmaceutical; medicines; research; health; industry
healthcare; pharmaceutical; medicines; research; health; industry

38 followers
About
EFPIA's posts

Post has attachment
Public
The Fresh New Face of Patient Engagement (Guest blog)

It is becoming increasingly clear that patient engagement across the entire lifecycle of medicines development is going to be key to securing the most beneficial outcomes for patients. The problem is that ‒ to date ‒ while there are many effective approaches and initiatives, they remain disparate and disjointed.



Post has attachment
Public
Ageing Nation’s Heritage to Benefit Registry-Based Research (Guest blog)

Five million Finns represent one of the most rapidly ageing populations in Europe. An ageing population translates into increasing future healthcare expenses.

The focus of public health problems is moving from cardiovascular diseases and mental health problems to cancers and neurological diseases. We know that the change is ongoing, but new information on its impact is still needed.

http://pharmaviews.eu/ageing-nations-heritage-to-benefit-registry-based-research-guest-blog/

Post has attachment
Public
Ageing Nation’s Heritage to Benefit Registry-Based Research (Guest blog)

Five million Finns represent one of the most rapidly ageing populations in Europe. An ageing population translates into increasing future healthcare expenses.

The focus of public health problems is moving from cardiovascular diseases and mental health problems to cancers and neurological diseases. We know that the change is ongoing, but new information on its impact is still needed.

http://pharmaviews.eu/ageing-nations-heritage-to-benefit-registry-based-research-guest-blog/

Post has attachment
Public
Statement from EFPIA President Joe Jimenez on the upcoming OECD Health Ministerial

On January 17, Health Ministers from OECD countries will gather in Paris, France, to discuss how healthcare systems can reform to better deal with the challenges and to realize the opportunities of tomorrow. Important milestones are on the agenda including how to tackle ineffective spending in healthcare and how health care systems should adapt to new technologies.

The challenges: an ageing population and the growing burden of chronic conditions such as cancer, diabetes, Alzheimer’s, and cardiovascular disease. Thanks to improvements in living conditions, socio-economic development and medical progress, we live longer than ever before. This is fundamentally a great achievement. However, as people get older, they often live with several chronic diseases at once. Healthcare systems face a dilemma of growing demand and the need to invest for the future, while budgets have been flat or declining following the global financial crisis.

http://efpia.eu/mediaroom/369/44/Statement-from-EFPIA-President-Joe-Jimenez-on-the-upcoming-OECD-Health-Ministerial

Post has attachment
Public
The Value of the Pharmaceutical Industry; key to Europe’s economy

The pharmaceutical industry continues to be a key driver of growth in the European economy. This is just one of the principle conclusions drawn by a new analysis of “The Economic Footprint of selected pharmaceutical companies in Europe”, carried out by the independent economic research institute, WifOR.

Specifically, the report looks at the economic impact of seven pharmaceutical companies – Abbvie, AstraZeneca, Boehringer Ingelheim, Ipsen, J&J, Novartis and Sanofi – and their contribution to the entire European economy from 2010 to 2014. While the report was funded by EFPIA and six of its member companies, these parties had no influence over the study questions, methods, analysis or the drafting.

http://efpia.eu/mediaroom/370/44/The-Value-of-the-Pharmaceutical-Industry-key-to-Europe-s-economy

Post has attachment
Public
EFPIA – IFPMA Statement in response to the OECD Health Committee Ministerial Statement

We welcome the Ministerial Statement from the OECD Health Committee, which seeks to address many important issues for health systems in OECD countries. Reducing waste and low-value care, to facilitate investment in the interventions that bring the most benefit to patients, is critical to the quality and sustainability of healthcare across OECD countries.

This evolution is predicated on better health data, and we therefore welcome warmly the Ministers’ focus on the utilisation of healthcare data and their ambition to collect patient-reported outcomes.

http://efpia.eu/mediaroom/371/43/EFPIA-IFPMA-Statement-in-response-to-the-OECD-Health-Committee-Ministerial-Statement

Post has attachment
Public
Building an Evidence-Based Approach to Improving Cancer Outcomes (Guest blog)

The International Cancer Benchmarking Partnership (ICBP) is a multidisciplinary collaboration of clinicians, academics, data experts and policymakers, across six countries with comparable health systems – Australia, Canada, Denmark, Norway, Sweden and the UK. The aim of the partnership is to understand how cancer survival varies and crucially to explore why these differences persist. ICBP research uses a range of data sources and methods to explore factors that could be contributing to international survival differences. The ultimate objective is to provide evidence for policymakers and clinicians to improve outcomes for cancer patients.

http://pharmaviews.eu/building-an-evidence-based-approach-to-improving-cancer-outcomes-guest-blog/

Post has attachment
Public
Clinical trials are only as credible as their outcomes (Guest blog)

Every year, hundreds of thousands of members of the public are recruited into tens of thousands of clinical trials in health and social care, and thousands of researchers prepare systematic reviews to bring together the findings of existing trials. Much of this effort is wasted if the outcomes measured and reported are not those needed by health service users, practitioners, health technology assessment (HTA) agencies, policy makers and others, making choices between or reimbursement decisions about different interventions, actions and strategies. Considering Peter Tugwell’s view that “Clinical trials are only as credible as their outcomes”, one can see this is equally true for systematic reviews, clinical guidelines, health technology assessments, and healthcare organisations.

http://pharmaviews.eu/clinical-trials-are-only-as-credible-as-their-outcomes-guest-blog/

Post has attachment
Public
Europe’s 21st century cure

One of the last acts of the Obama presidency may be one of its most significant. Cross-party alignment behind the 21st Century Cures Act seems sure to secure its passage and thus increase funding for the national institutes of health, while enabling the FDA to move towards a developing paradigm for drug approval based on patient outcomes.

http://pharmaviews.eu/europes-21st-century-cure/

Post has attachment
Public
The Value Pharma Places on Circular Economy

So why is a circular economy important to EFPIA? The driving motivation of the pharmaceutical industry is to improve human health and well-being. With nearly a quarter of global deaths attributable to the environment (UNEP, 2016. Healthy Environment, Healthy People), we recognise that reducing our environmental footprint is an important step we can take to positively impact human health. A shift to a circular economy could bring many health benefits. For example, optimising materials and processes to reduce our carbon footprint will help to combat climate change – described as the greatest opportunity to advance human health in the 21st Century.

http://pharmaviews.eu/the-value-pharma-places-on-circular-economy/
Wait while more posts are being loaded